Melanoma - historical
Jump to navigation
Jump to search
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the NCCN Guidelines. Is there a regimen missing from this list? See the main melanoma page for current regimens.
20 regimens on this page
34 variants on this page
|
Metastatic or unresectable disease
BCG & Dacarbazine
| back to top |
BCG & DTIC: Bacillus Calmette-Guérin & Dimethyl Triazeno Imidazole Carboxamide (Dacarbazine)
Regimen
| Study | Evidence |
|---|---|
| Gutterman et al. 1974 | Non-randomized |
Chemoimmunotherapy
References
- Gutterman JU, Mavligit G, Gottlieb JA, Burgess MA, McBride CE, Einhorn L, Freireich EJ, Hersh EM. Chemoimmunotherapy of disseminated malignant melanoma with dimethyl triazeno imidazole carboxamide and Bacillus Calmette--Guérin. N Engl J Med. 1974 Sep 19;291(12):592-7. link to original article PubMed
BVD
| back to top |
BVD: BCNU (Carmustine), Vincristine, Dacarbazine
Regimen
| Study | Evidence | Comparator | Efficacy |
|---|---|---|---|
| Jelić et al. 2002 | Phase III (C) | 1. High-dose BVD 2. Bleomycin, Cisplatin, Vindesine 3. Carmustine & Procarbazine |
Seems not superior |
Chemotherapy
References
- Jelić S, Babovic N, Kovcin V, Milicevic N, Milanovic N, Popov I, Radosavljevic D. Comparison of the efficacy of two different dosage dacarbazine-based regimens and two regimens without dacarbazine in metastatic melanoma: a single-centre randomized four-arm study. Melanoma Res. 2002 Feb;12(1):91-8. link to original article PubMed
CDB
| back to top |
CDB: Cisplatin, Dacarbazine, BCNU (Carmustine)
Regimen
| Study | Evidence | Comparator | Efficacy |
|---|---|---|---|
| Rusthoven et al. 1996 | Phase III (E) | CDB & Tamoxifen | Seems not superior |
| Creagan et al. 1999 | Phase III (C) | CDB & Tamoxifen | Seems not superior |
| Ridolfi et al. 2002 | Phase III (C) | Cisplatin, Dacarbazine, IL-2, IFN alfa-2b +/- Carmustine | Seems not superior |
Chemotherapy
References
- Rusthoven JJ, Quirt IC, Iscoe NA, McCulloch PB, James KW, Lohmann RC, Jensen J, Burdette-Radoux S, Bodurtha AJ, Silver HK, Verma S, Armitage GR, Zee B, Bennett K; National Cancer Institute of Canada Clinical Trials Group. Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. J Clin Oncol. 1996 Jul;14(7):2083-90. link to original article PubMed
- Creagan ET, Suman VJ, Dalton RJ, Pitot HC, Long HJ, Veeder MH, Vukov AM, Rowland KM, Krook JE, Michalak JC. Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma. J Clin Oncol. 1999 Jun;17(6):1884-90. link to original article PubMed
- Ridolfi R, Chiarion-Sileni V, Guida M, Romanini A, Labianca R, Freschi A, Lo Re G, Nortilli R, Brugnara S, Vitali P, Nanni O; Italian Melanoma Intergroup. Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial. J Clin Oncol. 2002 Mar 15;20(6):1600-7. link to original article contains verified protocol PubMed
Cisplatin, Dacarbazine, Interferon alfa-2b
| back to top |
Regimen
| Study | Evidence | Comparator | Efficacy |
|---|---|---|---|
| Keilholz et al. 2005 (EORTC 18951) | Phase III (C) | Cisplatin, Dacarbazine, IFN, IL-2 | Seems not superior |
Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm.
Chemotherapy
28-day cycle for up to 4 cycles
References
- EORTC 18951: Keilholz U, Punt CJ, Gore M, Kruit W, Patel P, Lienard D, Thomas J, Proebstle TM, Schmittel A, Schadendorf D, Velu T, Negrier S, Kleeberg U, Lehman F, Suciu S, Eggermont AM. Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol. 2005 Sep 20;23(27):6747-55. link to original article PubMed